WO2006125323A1 - Novel inhibitors of pyruvate kinase as therapeutic agents for cancer - Google Patents

Novel inhibitors of pyruvate kinase as therapeutic agents for cancer Download PDF

Info

Publication number
WO2006125323A1
WO2006125323A1 PCT/CA2006/000871 CA2006000871W WO2006125323A1 WO 2006125323 A1 WO2006125323 A1 WO 2006125323A1 CA 2006000871 W CA2006000871 W CA 2006000871W WO 2006125323 A1 WO2006125323 A1 WO 2006125323A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
subject
compound
pyruvate kinase
isomers
Prior art date
Application number
PCT/CA2006/000871
Other languages
French (fr)
Inventor
Brian Leyland-Jones
Brian R. Smith
Tak-Hang Chan
Original Assignee
Darwin Pharma Inc
Smith Brian R
Tak-Hang Chan
Brian Leyland-Jones
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Pharma Inc, Smith Brian R, Tak-Hang Chan, Brian Leyland-Jones filed Critical Darwin Pharma Inc
Priority to EP06741580A priority Critical patent/EP1891082A4/en
Priority to US11/915,664 priority patent/US8026278B2/en
Priority to CA2610647A priority patent/CA2610647C/en
Publication of WO2006125323A1 publication Critical patent/WO2006125323A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/02—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C305/14—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to acyclic carbon atoms of a carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3886—Acids containing the structure -C(=X)-P(=X)(XH)2 or NC-P(=X)(XH)2, (X = O, S, Se)
    • C07F9/3891—Acids containing the structure -C(=X)-P(=X)(XH)2, (X = O, S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
    • C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)

Definitions

  • the invention relates to novel inhibitors of pyruvate kinase and
  • the regulation in the rate of glycolysis is usually achieved by two glycolytic enzymes, one of which is pyruvate kinase (PK).
  • PK pyruvate kinase
  • the pyruvate kinase catalyzes the conversion of phosphoenol pyruvate (PEP) to pyruvate with the coupled transfer of the phosphoryl group from PEP to ADP giving ATP:
  • One aim of the present invention is to provide novel inhibitors of pyruvate kinase and ATP production for the treatment of cancer.
  • X represents a halide, a sulfonate, an alkoxide, an amine-oxide or sulfonium salt, or sulfoxide;
  • Y represents oxygen, sulphur or CH 2 ;
  • Z represents oxygen, sulphur or NR;
  • R and R' represent H, alkyl, aryl or heteroaryl esters; and any salts thereof.
  • a preferred inhibitor of the present invention is 2-bromo-1- oxoethylphosphonic acid.
  • an inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula Il : wherein,
  • X and Y represent H, halide, or alkyl group
  • R, R' and R" represent H, alkyl, aryl or heteroaryl esters; and any salts thereof.
  • a preferred inhibitor of the present invention comprises a compound of formula III:
  • X, Y, R R, R' and R" are as defined in claim 3; and any salts thereof.
  • a preferred inhibitor of the present invention is phosphoenol-3- bromopyruvic acid.
  • a preferred inhibitor of the present invention comprises a compound of formula IV: wherein
  • an inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula V :
  • X represents Cl or Br.
  • a preferred inhibitor of the present invention comprises a halide selected from the group consisting of: fluoride, bromide, chloride, and iodide.
  • a method of treating cancer in a subject comprising administering to the subject an effective amount of an inhibitor of the present invention.
  • the method may further comprising administering a second chemotherapeutic agent.
  • the second chemotherapeutic agent may be selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2- chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin-dunomycin, dexamethosone, doxurubicin, docetaxol, trastuzumab, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interfereon alfa n3, i
  • the effective amount of the inhibitor may be delivered by direct intraarterial injection or direct intravenous injection to a tumor, or using a delivery system, or administered orally to the patient such as in the form of a tablet, capsule or liquid.
  • the tumor may be selected from the group consisting of colorectal, glioma, liver, breast, lung or ovarian tumor.
  • the tumor may be a liver tumor and the inhibitor may be delivered to a hepatic artery.
  • the inhibitor may be delivered by transcatheteter hepatic artery injection.
  • the inhibitor or second chemotherapeutic agent may be delivered using a delivery system.
  • the delivery system may be selected from the group consisting of micelles, liposomes, transdermal and inhalation.
  • compositions for treating cancer in a subject comprising an effective amount of an inhibitor of the present invention in association with a pharmaceutically acceptable carrier.
  • the composition may further comprise a second chemotherapeutic agent.
  • the second chemotherapeutic agent may be selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2- chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin-dunomycin, dexamethosone, doxurubicin, docetaxol, trastuzumab, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interfereon alfa n3, i
  • novel inhibitors of PK and inhibitors of ATP production novel pharmaceutical compositions and methods of treatment of cancer thereof.
  • the compound was prepared according to literature procedures (M. J. Sparkes, H. B. F. Dixon, Biochemical Journal, 275, 772 (1991 )). The compound was made by brominating dimethyl acetylphosphonate and de-esterifying with HBr. Chemical synthesis of III, phosphoenol-3-bromopyruvic acid as the cyclohexylammonium salt.
  • the compound was prepared according to literature procedures (J. A. Stubbe, G. L. Kenyon, Biochemistry, 10, 2669 (1971 )).
  • Dimethyl phosphoenol-3-bromopyruvic acid (0.4 g) was dissolved in water (20 ml) and left at room temperature for 0.5 hr. The solvent was then removed in vacuo to give the crude phosphoenol-3- bromopyruvic acid.
  • a solution of cyclohexylamine (0.16 g) in water (10 ml) was then added, and after several minutes, the water was removed in high vacuum. The solid residue was recrystallized from methanol-ether to give cyclohexylammonium dihydrogen phosphoenol-3-bromopyruvate (0. 37 g, 73% yield), mp 125-127° (dec).
  • Trimethylsilyl bromide (2 mmol, 0.27 ml) was slowly added to a flask containing the above compound (1 mmol) under argon at 0-4 0 C. The mixture was stirred for 1 h and then for an additional 1 h at room temperature. After removal of excess trimthylsilyl bromide at high vacuum, cyclohexylamine (2 mmol) in methanol/ether (15 ml) was added. The white solid was collected by filtration and washed with ether to give dicyclohexylammonium ethyl 3-chlorophosphoenolpyruvate (0.30 g, 71% yield).
  • the Z-isomer started to elute at 0.19 M, whereas the E-isomer appeared at 0.27 M KCI.
  • the corresponding fractions were pooled and diluted three times with deionized water. They were loaded on a second Sephadex DEAE A-25 column (HCO 3 - form) and eluted with 2 ml/min triethylammonium bicarbonate (02 M to 1 M in 475 min). The fractions containing the product were pooled and lyophilized.
  • a pharmaceutical composition that contains an effective amount of one or more of the compounds of this invention and a pharmaceutically acceptable carrier for treating cancer related diseases.
  • the present invention covers a method of administering an effective amount of such a compound to a subject in need of treatment for cancer related diseases.
  • An effective amount refers to the amount of the compound which is required to confer a therapeutic effect on the treated subject.
  • An effective amount of the compounds of this invention can range from about 0.001 mg/kg to about 1000 mg/kg. Effective doses will vary, as recognized by those skilled in the art, depending on the diseases treated, route of administration, pharmaceutic! ⁇ acceptable carrier usage, and the possibility of co-usage with other therapeutic treatments such as use of other agents.
  • the compounds of the invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection direct intravenous injection to a tumor or using a delivery system.
  • the delivery system may be selected from the group consisting of micelles, liposomes, transdermal and inhalation.
  • a composition for oral administration can be any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.
  • carriers which are commonly used include lactose and corn starch.
  • useful diluents include lactose and dried corn starch.
  • the carrier in the pharmaceutical composition is "acceptable" in the sense of being compatible with the active ingredient of the formulation (and preferably, capable of stabilizing it) and not deleterious to the subject to be treated.
  • the compounds of the invention can be used to treat a tumor which may be selected from but not limited to the group consisting of colorectal, glioma, liver, breast, lung or ovarian tumor.
  • the tumor may be a liver tumor and the inhibitor may be delivered to a hepatic artery.
  • the inhibitor may be delivered by transcatheteter hepatic artery injection.
  • the composition may further comprise a second chemotherapeutic agent.
  • the second chemotherapeutic agent may be selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2-chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin-dunomycin, dexamethosone, doxurubicin, docetaxol, trastuzumab, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, inter
  • ester linkage It is possible to bridge potential PK inhibitor with other bioactive agents through the ester linkage.
  • the ester linkage will be readily hydrolyzed by esterases in the cell to give the active PK inhibitor as well the other bioactive agent.
  • Some possible structures are V and VIII.
  • compound V can be hydrolyzed by the intracellular esterases to give the PK inhibitor Vl and the cis-platin analog VII, both of which can act as cytotoxic agents.
  • compound VIII can be hydrolyzed by esterases to give the PK inhibitor Vl and retinol (IX) which can be in situ converted by enzymatic oxidation to retinoic acid (X), a known differentiating agent.
  • Acetyl chloride (7.85 ml, 110 mmol) was cooled to O 0 C and stirred. Trimethylphosphite (11.8 ml, 100 mmol) was added drop-wise over one hour while the cooling was maintained. The mixture was then heated to 8O 0 C for 5 minute to remove un-reacted acetyl chloride (the flow of argon accelerates the process). The crude product was used in the next step without additional purification (theoretical yield is 15.2 g).
  • the crude product from Step 3 was dissolved in 100 ml mixture of water and ice. Cyclohexylamine was added under cooling and stirring in sufficient amount (approx 5ml) to adjust pH till 3. The solution was again evaporated to dryness, and traces of water were removed by co- evaporation with ethanol. A solid formed which was triturated five times with ethanol and five times with methanol to remove the cyclohexylammmonium salts of HBr 1 acetic acid and acetylphosphonic acid. The solid product was dissolved in methanol (200 ml) and precipitated by the addition of diethyl ether (2L). The precipitate was filtered and dried to give 3 g of the crude target.
  • a solution of bromine (15 ml, 46.8 g, 29.3 mmol) in chloroform (100 ml) was prepared. A few drops of this solution were added to a solution of pyruvic acid (11.7 g, 13.3 mmol) in chloroform (100 ml) and stirred until decolorization began (in 10-15 minutes). Then half of the bromine solution was added to the reaction mixture drop-wise with stirring with the rate providing almost complete discoloration of bromine. The remainder of the bromine solution was then added at once. The reaction mixture was heated until boiling and refluxed for 20 hours.
  • a reaction flask was dried by heating under argon for 5 minutes. After cooling to room temperature it was charged with a solution of trimethyl phosphite (6.2 g, 5.9 ml, 50 mmol) in anhydrous diethyl ether (20 ml). After cooling the reaction mixture with an ice/water bath for 20 minutes, the solution of 3,3-dibromopyruvic acid (9.84 g, 40 mmol) in anhydrous diethyl ether (20 ml) was added at once. Gas evolution began after approximately 2 minutes and continued for several seconds. Then the reaction mixture was allowed to heat to ambient temperature and stirred for an additional 2 hours.
  • reaction mixture was evaporated under reduced pressure until dryness and kept under vacuum for 1 hour to remove the excess trimethylphosphite.
  • the remaining substance was dissolved in water (50 ml) and stirred for 30 minutes. The resulting solution was used further without isolation of 3,3 dibromopyruvic acid.
  • a dry 3-neck 500 ml round bottom flask was equipped with a condenser and Ar inlet and outlet.
  • Ethyl pyruvate 48 g, 431 mmol, 1 eq
  • p-toluenesulfonic acid monohydrate 8 g, 42 mmol
  • SO 2 CI 2 39 ml
  • Additional SO 2 CI 2 was added in 50 ml aliquots at 4 hour, 6 hour and 22 hour reaction times (total amount of SO 2 CI 2 189 ml, 317.5 g, 2.35 mol, 5.5 eq).
  • the reaction mixture was allowed to cool to ambient temperature and evaporated on a rotary evaporator at a bath temperature of 5O 0 C under vacuum.
  • the crude product was mixed with 80 ml of cold water and extracted with diethyl ether (3 x 50 ml). The ether layer was washed with water (50 ml), brine (50 ml) and dried over anhydrous MgSO 4 . After filtration, the ether layer was concentrated on a rotary evaporator to get 66.65 g of a yellow oil. The yield of the crude product was 84%. The product was used on the next step without additional purification.
  • Trimethylphosphite (53.42 ml, 453 mmol, 1.8 eq) was charged into the flask under an Ar atmosphere and cooled with ice bath to
  • the product from Step 3 (18.8 g, 45.53 mmol, 1 eq) was dissolved in water (20 ml) in a 500 ml round bottom flask and cooled with an ice bath to O 0 C. Approximately 182 ml of a 1 M KOH solution was added portion-wise over 5 minutes. The reaction mixture was stirred for an additional 8 hours at ambient temperature and kept in a fridge at 5 0 C for approximately 15 hours. The reaction mixture was neutralized with 150 ml of a 1 M HCI solution and rotary evaporated at bath temperature of 25 0 C. This gave 32 g of the wet crude product (containing 1 :4 ratio of the two isomers plus phosphoenol pyruvate).
  • Step 4 This procedure was repeated until all the product of Step 4 was chromatographed.
  • the combined fractions from the columns containing the individual isomers were subjected to a second anion-exchange chromatography for transformation to the triethylammonium salt.
  • the linear gradient was generated by the addition of a 1 M solution of triethylammonium bicarbonate at a rate of 4 ml/min into a reservoir containing 500 ml of water. 10 ml fractions were monitored by UV-VIS spectroscopy at 254 nm. Fractions 42 to 72 contained the product. The pooled fractions were stored in the fridge.
  • pooled fractions from the columns were combined, rotary evaporated under vacuum at ambient temperature, co-evaporated with methanol to remove excess TEA and co-evaporated with acetronitrile to remove excess water.
  • E-3-chlorophosphoenolpyruvate ditriethyl- ammonium salt (ECPDAT), Z-3- chlorophosphoenolpyruvate tritriethyl- ammonium salt (CPTP), phosphoenol-3-bromo-pyruvic acid mono- cyclohexyl ammonium salt (PBPA), 2-bromooxoethylphosphonic acid mono-cyclohexyl-ammonium salt (BOEPA) and 3-bromopyruvic acid (BrPyA) were tested for their efficiency at inhibiting pyruvate kinase. Pyruvate kinase isolated from rabbit muscle was purchased from Sigma- Aldrich.
  • Pyruvate kinase was assayed indirectly by quantifying ADP production formed in the reaction ATP + pyruvate to ADP + phosphoenolpyruvate. Inhibitors were added to the reaction mixture immediately before the reaction was started by the addition of ATP. E- CPDA, CPTP and PBPA inhibited pyruvate kinase at lower concentrations than BrPyA.
  • MCF7 breast
  • SF268 glioma
  • MTT 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide
  • the MTT assay is well known in the art (see for example Slater et al., Biochim. Biophys. Acta 77(1963) 383).
  • the cells were incubated with a given inhibitor for 72 hours and assayed.
  • ECPDA, CPTP, PBPA and BOEPA inhibited cell proliferation in both MCF7 and SF268 cells.
  • PBPA uM I 0 10 25 50 75 100 200 300 500 I
  • NC no cells
  • A-Blank Average-Blank
  • % [A-blank]-[A-Blank]c o n t roi/[A- Blank] c on t roi
  • SEM Standard error of the mean. Concentrations are in ⁇ M and the data are O. D. readings at 570nm.

Abstract

The present invention relates to compounds for the inhibition of pyruvate kinase and ATP production which are capable of inhibiting cancer cells proliferation.

Description

NOVEL INHIBITORS OF PYRUVATE KINASE AS THERAPEUTIC
AGENTS FOR CANCER
BACKGROUND OF THE INVENTION
(a) Field of the Invention The invention relates to novel inhibitors of pyruvate kinase and
ATP production specific for the treatment of cancer, pharmaceutical compositions and methods of treatment of cancer thereof.
(b) Description of Prior Art
Most malignant tumors have much higher glucose uptake and glycolysis rates than noncancerous tissues. This is characteristic for many human tumors (including those of brain, liver, lung, colon, stomach and breast). The higher metabolism of glucose is needed by the tumor cells for
ATP production, via the glycolysis pathway resulting in pyruvate and ATP:
Glucose + 2 NAD+ + 2ADP + 2P1 → 2 pyruvate + 2NADH + 2H+ + 2ATP + 2 H2O
The regulation in the rate of glycolysis is usually achieved by two glycolytic enzymes, one of which is pyruvate kinase (PK). The pyruvate kinase catalyzes the conversion of phosphoenol pyruvate (PEP) to pyruvate with the coupled transfer of the phosphoryl group from PEP to ADP giving ATP:
PK
PEP + ADP → pyruvate + ATP
Several isoforms of pyruvate kinase are known in a tissue- specific manner, such as. L-PK in liver and kidney and M1-PK in brain and muscle. During multi-step carcinogenesis, there is the loss of the tissue- specific isoforms of PK, followed by the expression of the tumor M2-PK (E. Eigenbrodt et al., Crti. Reve. Oncog. 3 (1992) 91-115.). Recently the use of the detection of tumor M2-PK as a marker for cancer monitoring, including renal cell carcinoma, gastrointestinal cancer (J. Schneider, G. Schulze, Anticancer Research, 23 (2003) 5089-5093), breast cancer (S. Yilmaz, S. Ozan, I. H. Ozercan, Arch Med Res 34 (2003) 315-324) and lung cancer (J. Schneider et al., Cancer Letters, 193 (2003) 91-98) has been advocated. lnhibition of ATP production is a plausible strategy for the treatment of cancer. Recently, the use of 3-bromopyruvic acid (3-BrPA) in a direct intraarterial injection to suppress implanted rabbit liver tumors has been reported (J. -F. H. Geschwind et al., Cancer Research, 62 (2002) 3909-3913; US patent application published under No. US 2003/0087961 on May 8, 2003). The inhibition of ATP production via inhibition of hexokinase using 3-bromopyruvic acid (3-BrPA) has been suggested (Y. H. Ko et al., Cancer Letters, 173 (2001 ) 83-91 ), however there is a need for novel inhibitors of ATP production which are more stable and efficacious. It would be highly desirable to be provided with novel inhibitors of pyruvate kinase and ATP production specific for the treatment of cancer.
SUMMARY OF THE INVENTION
One aim of the present invention is to provide novel inhibitors of pyruvate kinase and ATP production for the treatment of cancer.
In accordance with one embodiment of the present invention there is provided an inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula I :
Figure imgf000003_0001
wherein,
X represents a halide, a sulfonate, an alkoxide, an amine-oxide or sulfonium salt, or sulfoxide;
Y represents oxygen, sulphur or CH2; Z represents oxygen, sulphur or NR;
R and R' represent H, alkyl, aryl or heteroaryl esters; and any salts thereof.
A preferred inhibitor of the present invention is 2-bromo-1- oxoethylphosphonic acid. In accordance with another embodiment of the present invention there is provided an inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula Il :
Figure imgf000004_0001
wherein,
X and Y represent H, halide, or alkyl group; A is
O
Figure imgf000004_0002
R, R' and R" represent H, alkyl, aryl or heteroaryl esters; and any salts thereof.
A preferred inhibitor of the present invention comprises a compound of formula III:
Figure imgf000004_0003
wherein
X, Y, R R, R' and R" are as defined in claim 3; and any salts thereof.
A preferred inhibitor of the present invention is phosphoenol-3- bromopyruvic acid.
A preferred inhibitor of the present invention, comprises a compound of formula IV:
Figure imgf000005_0001
wherein
X, Y, R R, R' and R" are as defined in claim 3; and any salts thereof. In accordance with another embodiment of the present invention there is provided an inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula V :
Figure imgf000005_0002
wherein X represents Cl or Br.
In accordance with another embodiment of the present invention there is provided an inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula VIII :
Figure imgf000005_0003
wherein
X represents Cl or Br.
A preferred inhibitor of the present invention comprises a halide selected from the group consisting of: fluoride, bromide, chloride, and iodide.
In accordance with another embodiment of the present invention there is provided a method of treating cancer in a subject comprising administering to the subject an effective amount of an inhibitor of the present invention. The method may further comprising administering a second chemotherapeutic agent.
The second chemotherapeutic agent may be selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2- chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin-dunomycin, dexamethosone, doxurubicin, docetaxol, trastuzumab, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interfereon alfa n3, irinotecan, leucovorin calcium, leuprolide, levamisole, lomustine, inegestrol, melphalan, L-sarcosylin, melphalan hydrochloride, MESNA, mechlorethamine, methotrexate, mitomycin, mitoxantrone, mercaptopurine, paclitaxel, plicamycin, prednisone, procarbazine, streptozocin, tamoxifen, 6-thioguanine, thiotepa, vinblastine, vincristine and vinorelbine tartrate.
The effective amount of the inhibitor may be delivered by direct intraarterial injection or direct intravenous injection to a tumor, or using a delivery system, or administered orally to the patient such as in the form of a tablet, capsule or liquid.
The tumor may be selected from the group consisting of colorectal, glioma, liver, breast, lung or ovarian tumor.
The tumor may be a liver tumor and the inhibitor may be delivered to a hepatic artery. The inhibitor may be delivered by transcatheteter hepatic artery injection.
The inhibitor or second chemotherapeutic agent may be delivered using a delivery system.
The delivery system may be selected from the group consisting of micelles, liposomes, transdermal and inhalation.
In accordance with another embodiment of the present invention there is provided a composition for treating cancer in a subject comprising an effective amount of an inhibitor of the present invention in association with a pharmaceutically acceptable carrier. The composition may further comprise a second chemotherapeutic agent.
The second chemotherapeutic agent may be selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2- chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin-dunomycin, dexamethosone, doxurubicin, docetaxol, trastuzumab, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interfereon alfa n3, irinotecan, leucovorin calcium, leuprolide, levamisole, lomustine, inegestrol, melphalan, L-sarcosylin, melphalan hydrochloride, MESNA, mechlorethamine, methotrexate, mitomycin, mitoxantrone, mercaptopurine, paclitaxel, plicamycin, prednisone, procarbazine, streptozocin, tamoxifen, 6-thioguanine, thiotepa, vinblastine, vincristine and vinorelbine tartrate.
All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided novel inhibitors of PK and inhibitors of ATP production, novel pharmaceutical compositions and methods of treatment of cancer thereof.
Chemical synthesis of I, 2-bromo-1-oxoethylphosphonic acid
Figure imgf000007_0001
The compound was prepared according to literature procedures (M. J. Sparkes, H. B. F. Dixon, Biochemical Journal, 275, 772 (1991 )). The compound was made by brominating dimethyl acetylphosphonate and de-esterifying with HBr. Chemical synthesis of III, phosphoenol-3-bromopyruvic acid as the cyclohexylammonium salt.
Figure imgf000008_0001
The compound was prepared according to literature procedures (J. A. Stubbe, G. L. Kenyon, Biochemistry, 10, 2669 (1971 )).
Dimethyl phosphoenol-3-bromopyruvic acid (0.4 g) was dissolved in water (20 ml) and left at room temperature for 0.5 hr. The solvent was then removed in vacuo to give the crude phosphoenol-3- bromopyruvic acid. A solution of cyclohexylamine (0.16 g) in water (10 ml) was then added, and after several minutes, the water was removed in high vacuum. The solid residue was recrystallized from methanol-ether to give cyclohexylammonium dihydrogen phosphoenol-3-bromopyruvate (0. 37 g, 73% yield), mp 125-127° (dec).
Chemical synthesis of III, 3-chlorophosphoenolpyruvic acid, as the ditriethylammonium salt
Figure imgf000008_0002
This compound was prepared according to literature procedures (L. F. Carcia-Alles, B. Erni, Eur. J. Biochem., 269, 3226 (2002)).
To trimethyl phosphite (10 mmol) cooled at 0-100C was added dropwise ethyl dichloropyruvate (10 mmol). After addition, the ice-bath was removed and the reaction was allowed to proceed at 7O0C for one hour to give the ethyl/dimethyl ester of 3-chlorophosphoenolpyruvate. It was purified by flash chromatography (hexanes/ethyl acetate, 1 :1 , v/v) to give 1.5 g (58% yield) of 4:1 mixture of the Z- and E-isomers. Trimethylsilyl bromide (2 mmol, 0.27 ml) was slowly added to a flask containing the above compound (1 mmol) under argon at 0-40C. The mixture was stirred for 1 h and then for an additional 1 h at room temperature. After removal of excess trimthylsilyl bromide at high vacuum, cyclohexylamine (2 mmol) in methanol/ether (15 ml) was added. The white solid was collected by filtration and washed with ether to give dicyclohexylammonium ethyl 3-chlorophosphoenolpyruvate (0.30 g, 71% yield).
The above salt (1.2 g, 2.8 mmol) was hydrolysed by the addition of aqueous KOH (1 M, 5 mol eq.). The solution was kept at pH 12.5 for 5 h and then neutralized with 1 M HCI (final pH value =6.0). The mixture was diluted with deionized water (300 ml) and slowly loaded at 40C to a Sephadex DEAE A-25 column (30 g, Cl- form) which was then eluted with a KCI gradient (2 ml/min, 10 ml per fraction, 0.15 M to 0.35 M in 475 min). the compounds were detected at 254 nm. The Z-isomer started to elute at 0.19 M, whereas the E-isomer appeared at 0.27 M KCI. The corresponding fractions were pooled and diluted three times with deionized water. They were loaded on a second Sephadex DEAE A-25 column (HCO3- form) and eluted with 2 ml/min triethylammonium bicarbonate (02 M to 1 M in 475 min). The fractions containing the product were pooled and lyophilized. Analytical HPLC [DEAE-60-7 column, 1 ml/min, 20 mM KH2PO4, pH=6.0, KCI (0 mM for 2 min to 360 mM in 16 min)] revealed that the isolated products were more than 99% pure. Retention time for the Z- isomer as ditriethylammonium salt, 13.2 min, 0.47 g, 42% yield; for the E- isomer as ditriethylammonium salt, 16.0 min, 0.11 g, 10% yield.
Chemical synthesis of IV, 3-chloro-sulfoenolpyruvate, as the potassium salt
Figure imgf000009_0001
The synthesis was based on a modification of the procedures used for the synthesis of sulfoenolpyruvate (J. A. Peliska, M. H. O'Leary, Biochemistry, 28, 1604 (1989)).
Also within the scope of this invention is a pharmaceutical composition that contains an effective amount of one or more of the compounds of this invention and a pharmaceutically acceptable carrier for treating cancer related diseases. Further, the present invention covers a method of administering an effective amount of such a compound to a subject in need of treatment for cancer related diseases. "An effective amount" refers to the amount of the compound which is required to confer a therapeutic effect on the treated subject. An effective amount of the compounds of this invention can range from about 0.001 mg/kg to about 1000 mg/kg. Effective doses will vary, as recognized by those skilled in the art, depending on the diseases treated, route of administration, pharmaceutic!^ acceptable carrier usage, and the possibility of co-usage with other therapeutic treatments such as use of other agents.
The compounds of the invention, as a component of a pharmaceutical composition, can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection direct intravenous injection to a tumor or using a delivery system. The delivery system may be selected from the group consisting of micelles, liposomes, transdermal and inhalation.
A composition for oral administration can be any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. For oral administration in a capsule form, useful diluents include lactose and dried corn starch.
The carrier in the pharmaceutical composition is "acceptable" in the sense of being compatible with the active ingredient of the formulation (and preferably, capable of stabilizing it) and not deleterious to the subject to be treated. In one embodiment the compounds of the invention can be used to treat a tumor which may be selected from but not limited to the group consisting of colorectal, glioma, liver, breast, lung or ovarian tumor.
The tumor may be a liver tumor and the inhibitor may be delivered to a hepatic artery. The inhibitor may be delivered by transcatheteter hepatic artery injection.
The composition may further comprise a second chemotherapeutic agent. The second chemotherapeutic agent may be selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2-chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin-dunomycin, dexamethosone, doxurubicin, docetaxol, trastuzumab, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interfereon alfa n3, irinotecan, leucovorin calcium, leuprolide, levamisole, lomustine, inegestrol, melphalan, L-sarcosylin, melphalan hydrochloride, MESNA, mechlorethamine, methotrexate, mitomycin, mitoxantrone, mercaptopurine, paclitaxel, plicamycin, prednisone, procarbazine, streptozocin, tamoxifen, 6-thioguanine, thiotepa, vinblastine, vincristine and vinorelbine tartrate.
The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.
EXAMPLE 1
Chemical structures which bridge PK inhibitor with other bioactive agents
It is possible to bridge potential PK inhibitor with other bioactive agents through the ester linkage. Within the cancer cell, the ester linkage will be readily hydrolyzed by esterases in the cell to give the active PK inhibitor as well the other bioactive agent. Some possible structures are V and VIII. For example, compound V can be hydrolyzed by the intracellular esterases to give the PK inhibitor Vl and the cis-platin analog VII, both of which can act as cytotoxic agents.
Figure imgf000012_0001
Similarly, compound VIII can be hydrolyzed by esterases to give the PK inhibitor Vl and retinol (IX) which can be in situ converted by enzymatic oxidation to retinoic acid (X), a known differentiating agent.
Figure imgf000012_0002
EXAMPLE 2
Additional details on the synthesis of I, 2-bromo-1- oxoethylphosphonic acid
All reagents were purchased form Aldrich and used as received unless other-wise stated. 1D, 2D and 31P NMR were run on a Varian 500MHz spectrometer.
Step 1 Synthesis of dimethyl acetylphosphonate
Acetyl chloride (7.85 ml, 110 mmol) was cooled to O0C and stirred. Trimethylphosphite (11.8 ml, 100 mmol) was added drop-wise over one hour while the cooling was maintained. The mixture was then heated to 8O0C for 5 minute to remove un-reacted acetyl chloride (the flow of argon accelerates the process). The crude product was used in the next step without additional purification (theoretical yield is 15.2 g).
Analytical data: 1H-NMR (CDCI3, δ, ppm): 2.26 (d, 3H), 3.64 (d, 6H).
Step 2 Synthesis of Dimethyl 2-bromoacetylphosphonate
A few drops of bromine were added to the crude product from Step 1 and the reaction mixture was stirred and slowly warmed until decolourization started (approximately at 5O0C). The remainder of the bromine (2.6 ml, 50 mmol) was added slowly with cooling to keep the temperature below 5O0C. We used less than the theoretical quantity of bromine to avoid formation of dibromoacetyl-phosphonate.
Analytical data:
1H-NMR (CDCI3, δ, ppm): 3.64 (d, 6H), 4.26 (d, 2H) Step 3 Synthesis of 2-Bromoacetylphosphonic acid
To the crude product from the previous step was added 25 ml of 33% solution of HBr in acetic acid at room temperature. The mixture was kept at room temperature overnight and evaporated under reduced pressure to dryness.
Analytical data:
1H-NMR (D2O, δ, ppm): 4.68 (br.s)
Step 4 Synthesis of Cyclohexylammonium salt of 2-bromoacetyl- phosphonic acid
The crude product from Step 3 was dissolved in 100 ml mixture of water and ice. Cyclohexylamine was added under cooling and stirring in sufficient amount (approx 5ml) to adjust pH till 3. The solution was again evaporated to dryness, and traces of water were removed by co- evaporation with ethanol. A solid formed which was triturated five times with ethanol and five times with methanol to remove the cyclohexylammmonium salts of HBr1 acetic acid and acetylphosphonic acid. The solid product was dissolved in methanol (200 ml) and precipitated by the addition of diethyl ether (2L). The precipitate was filtered and dried to give 3 g of the crude target. This was re-precipitated from a mixture of 150 ml of methanol and 1.5 L of diethyl ether then dried under vacuum for 16 hours giving 2.7g of pure compound 5 (8.9% overall) as the mono- cyclohexamine salt.
Analytical data:
1H -NMR (CD3OD, δ, ppm): 4.64 (2H), 3.08 (1H), 1.25 - 2.04 (10H). 13C-NMR (CD3OD, ppm): 25.7, 26.1 , 32.1 , 39.0, 51.6 (cyclohexylamine),
39.9 (CH2Br), 209.8, 212.1 (C=O).
31P-NMR (CD3OD, ppm): -4.77.
MS: m/z 200.9, 202.9 (M-H)'; m/z 121 , 123 (M-H-Br); 218.9, 220.9 (M-
H+water) Water content: 3.0 % w/w (Karl Fischer). EXAMPLE 3
Additional details on the synthesis of phosphoenol-3-bromopyruvic acid
All reagents were purchased form Aldrich and used as received unless other-wise stated. 1H, 13C, DEPT135, HSQC, HMBC, COSY, 2D and 31P NMR were run on a Varian 500MHz spectrometer.
Preparation of 3,3-dibromopyruvic acid
A solution of bromine (15 ml, 46.8 g, 29.3 mmol) in chloroform (100 ml) was prepared. A few drops of this solution were added to a solution of pyruvic acid (11.7 g, 13.3 mmol) in chloroform (100 ml) and stirred until decolorization began (in 10-15 minutes). Then half of the bromine solution was added to the reaction mixture drop-wise with stirring with the rate providing almost complete discoloration of bromine. The remainder of the bromine solution was then added at once. The reaction mixture was heated until boiling and refluxed for 20 hours.
After cooling the reaction mixture to room temperature, white crystals precipitated. The solid was filtered off, washed on filter with chloroform (3 x 10 ml), dried on air and over P2OsTlIe mother liquor was concentrated and an additional quantity of the product was obtained. The total yield of the product was 12.8 g (40.2%).
Analytical data:
1H-NMR (δ, D2O) - 5.96 ppm (s, 1 H).
Melting point - 82-840C.
Preparation of cvclohexylammonium salt of phosphoenol-3- bromopyruvate
A reaction flask was dried by heating under argon for 5 minutes. After cooling to room temperature it was charged with a solution of trimethyl phosphite (6.2 g, 5.9 ml, 50 mmol) in anhydrous diethyl ether (20 ml). After cooling the reaction mixture with an ice/water bath for 20 minutes, the solution of 3,3-dibromopyruvic acid (9.84 g, 40 mmol) in anhydrous diethyl ether (20 ml) was added at once. Gas evolution began after approximately 2 minutes and continued for several seconds. Then the reaction mixture was allowed to heat to ambient temperature and stirred for an additional 2 hours.
Analytical Data 1H-NMR (δ, D2O): 7.10 ppm (d, 1 H); 3.51 ppm (d, 3 H); 3.49 ppm (d, 3 H)
The reaction mixture was evaporated under reduced pressure until dryness and kept under vacuum for 1 hour to remove the excess trimethylphosphite. The remaining substance was dissolved in water (50 ml) and stirred for 30 minutes. The resulting solution was used further without isolation of 3,3 dibromopyruvic acid.
A solution of cyclohexylamine (4.6 ml, 40 mmol) in water (10 ml) was added to the entire amount of crude reaction mixture (approx. 15 g in 50 ml water) and stirred for 5 minutes. Water was evaporated under vacuum and the solid residue was dried under high vacuum for 1 hour. It was dissolved in methanol (50 ml) and diluted with diethyl ether (500 ml) while stirring. A white precipitate formed. The suspension was stirred overnight, filtered, the solid washed with diethyl ether (100 ml) and air dried to give 900 mg of product. An additional quantity of product was obtained from the mother liquor. Total yield of the product was 1240 mg.
The product was purified by dissolution in water (12.5 ml) at ambient temperature and dilution with acetonitrile (650 ml). The precipitate was filtered off and air dried. Yield of the purified product was 1090 mg. The purified product was washed with acetonitrile (30 ml) by stirring, filtered and air dried. Final yield of cyclohexylammonium dihydrogen phosphoenol-3-bromopyruvate was 870 mg (6.5%). Analvtical data:
1H-NMR (δ, DMSO-de): 6.90 ppm (d, 1 H), 2.92 ppm (br. m, 1 H), 1.07 - 1.88 ppm (m, 10 H);
13C-NMR (DMSO-CJ6, ppm): 23.5, 23.7, 24.6, 30.3, 30.5, 49.3 (all - cyclohexylamine); 105.4 (CHBr), 145.6 [COPO(OH)2], 163.6 (COOH); 31P-NMR (CD3OD): -3.65 ppm
MS: m/Z 246.9 (M-1 ), 244.9 (M-1), 228.9 (M-I-H2O), 226.9 (M-I-H2O), 166.8 (M-Br), 165.0 (M-Br);
Water content: 0.83 % w/w (Karl Fisher); Melting point: 1250C (dec).
EXAMPLE 4
Additional details on the synthesis of 3-chlorophosphoenolpyruvic acid
EXPERIMENTAL
All reagents were purchased from Aldrich and used as received uunnlleessss ootthheerr--wwiissee ssttaatted. 1 D, 2D and 31P NMR were run on a Varian 500MHz spectrometer.
Step 1 Synthesis of ethyl 3,3-dichloropyruvate
A dry 3-neck 500 ml round bottom flask was equipped with a condenser and Ar inlet and outlet. Ethyl pyruvate (48 g, 431 mmol, 1 eq), p-toluenesulfonic acid monohydrate (8 g, 42 mmol) and SO2CI2 (39 ml) were mixed and refluxed under Ar at 7O0C. Additional SO2CI2 was added in 50 ml aliquots at 4 hour, 6 hour and 22 hour reaction times (total amount of SO2CI2 189 ml, 317.5 g, 2.35 mol, 5.5 eq). After reflux for 45 hours, the reaction mixture was allowed to cool to ambient temperature and evaporated on a rotary evaporator at a bath temperature of 5O0C under vacuum. The crude product was mixed with 80 ml of cold water and extracted with diethyl ether (3 x 50 ml). The ether layer was washed with water (50 ml), brine (50 ml) and dried over anhydrous MgSO4. After filtration, the ether layer was concentrated on a rotary evaporator to get 66.65 g of a yellow oil. The yield of the crude product was 84%. The product was used on the next step without additional purification.
Step 2 Synthesis of ethyl dimethyl 3-chlorophosphoenolpyruvate
A dry 3-neck 250 ml round bottom flask was equipped with a dropping funnel. Trimethylphosphite (53.42 ml, 453 mmol, 1.8 eq) was charged into the flask under an Ar atmosphere and cooled with ice bath to
-1O0C. Crude Ethyl 3,3-dichloropyruvate (47.72 g, 258 mmol, 1 eq) was added drop wise over 65 minutes. The cooling bath was replaced with oil bath, the mixture was heated at 700C for 2 hours. The stirring was continued at ambient temperature for approximately 9 hours. The reaction mixture was concentrated to get 60 g of a yellow oil as crude product. The crude yield was 90%.
Analytical data; Z-isomer
1H-NMR (δ, D2O, ppm): 6.84 (s, 1 H), 4.38-4.28 (q, 2 H), 3.97 (s, 3 H); 3.94 (s, 3 H); 1.39-1.32 (t, 3 H).
E-isomer
1H-NMR (δ, D2O, ppm): 7.10 (s, 1 H), 4.38-4.28 (q, 2 H), 3.90 (s, 3 H); 3.87 (s, 3 H); 1.39-1.32 (t, 3 H).
Step 3 Synthesis of ethyl 3-chlorophosphoenolpyruvate dicyclohexyl- ammonium salt
The crude product from Step 2 (12.33 g, 47.68 mmol, 1 eq) was added to a dry one neck 100 ml round bottom flask. This was co- evaporated twice with anhydrous ethylacetate (2 x 40 ml). Anhydrous ethylacetate (40 ml) was then added and the solution cooled to O0C. Trimethylsilylbromide (20 ml, 150 mmol, 3 eq) was added drop wise over 5 minutes under an Argon atmosphere. The reaction mixture was stirred for an additional 2 hours at O0C then allowed to warm to ambient temperature. The excess trimethylsilylbromide was removed by rotary evaporation. A solution of cyclohexylamine (14.92 ml) in a mixture of methanol (145 ml) and diethyl ether (863 ml) was added to the reaction mixture at O0C. A white precipitate was filtered using a sintered glass filter funnel (Kimax 150ml-60M) and rinsed with diethyl ether (3 x 15 ml). During storage of the filtrate a second crop of the product formed. It was collected by filtration and rinsed with diethyl ether. After air drying, 18.92 g (96% yield) of a white solid was obtained.
Analytical data:
1H-NMR (δ, D2O, ppm): 6.87 (s, 1 H, E-isomer), 6.54 (s, 1 H, Z-isomer); 4.24-4.13 (q, 2 H, E- and Z-isomers); 3.02 (m, 2 H); 1.85 (m, 4 H); 1.68 (m, 4 H); 1.51-1.54 (m, 2 H); 1.16-1.24 (m, 11 H); 1.04-1.06 (m, 2 H).
Step 4 Synthesis of the potassium salt of 3- chlorophosphoenolpyruvic acid
The product from Step 3 (18.8 g, 45.53 mmol, 1 eq) was dissolved in water (20 ml) in a 500 ml round bottom flask and cooled with an ice bath to O0C. Approximately 182 ml of a 1 M KOH solution was added portion-wise over 5 minutes. The reaction mixture was stirred for an additional 8 hours at ambient temperature and kept in a fridge at 50C for approximately 15 hours. The reaction mixture was neutralized with 150 ml of a 1 M HCI solution and rotary evaporated at bath temperature of 250C. This gave 32 g of the wet crude product (containing 1 :4 ratio of the two isomers plus phosphoenol pyruvate).
Analytical data:
1H -NMR (D2O, δ, ppm): 6.79 (s, 1 H, E-isomer); 6.30 (s, 1 H, Z-izomer). Separation of E- and Z- isomers of Potassium salt of 3- chlorophosphoenol-pyruvic acid
Approximately 3.3 g of crude product from Step 4 was dissolved in 1 L of water and cooled with an ice bath. The cold solution was loaded onto a packed column [column height 65 cm, diameter 2.5 cm, stationary phase approximately 300 ml of sepharose-DEAE (chloride form)] with a flow rate of 2 ml/min. The loaded column was eluted with KCI solution (flow rate 2 ml/min) with linear increasing concentration gradient. The linear gradient was generated by addition of 0.35 M solution of KCI to 250 ml of 0.05 M solution of KCI with rate 2 ml/min. Fractions (10 ml each) were monitored by UV-VIS spectroscopy at 254nm wavelength. Fractions 73 to 98 contained the 1st isomer while fractions 104 to 124 contained 2nd isomer. The pooled fractions of each isomer were sealed and stored in the fridge.
This procedure was repeated until all the product of Step 4 was chromatographed. The combined fractions from the columns containing the individual isomers were subjected to a second anion-exchange chromatography for transformation to the triethylammonium salt.
Step 5 Synthesis of Triethylammonium salt of Z-3- chlorophosphoenol-pyruvic acid
Approximately 250 ml of the pooled fractions of the potassium salt of the isomer was diluted to 750 ml with water and cooled with ice. It was loaded onto a packed column (column height 65 cm, diameter 2.5 cm, stationary phase -300 ml of sepharose-DEAE (triethylammonium form)) with a flow rate of 4 ml/min. The loaded column was eluted first with 500 ml of cold water to remove the excess KCI solution then triethylammonium bicarbonate buffer solution with a linear increasing concentration gradient. The linear gradient was generated by the addition of a 1 M solution of triethylammonium bicarbonate at a rate of 4 ml/min into a reservoir containing 500 ml of water. 10 ml fractions were monitored by UV-VIS spectroscopy at 254 nm. Fractions 42 to 72 contained the product. The pooled fractions were stored in the fridge.
The pooled fractions from the columns were combined, rotary evaporated under vacuum at ambient temperature, co-evaporated with methanol to remove excess TEA and co-evaporated with acetronitrile to remove excess water.
Analytical data;
Z-isomer
1H-NMR (δ, D2O, ppm): 7.00 (S, 1 H), 3.09-3.15 (q, 18 H)1 1.18 - 1.22 (t, 27 H) 13C-NMR (D2O, ppm): 165.6, 141.7, 120.1 , 46.7, 8.2 31P-NMR (D2O): -4.41 ppm MS (ESI, negative mode, m/Z): 200.9, 203.0 (M-H). Water content: 1.72 % w/w (Karl Fisher).
E-isomer
1H-NMR (δ, D2O, ppm): 6.27 (s, 1 H), 3.11-3.16 (q, 18 H), 1.19 - 1.23 (t, 27
H) 13C-NMR (D2O, ppm): 166.1 , 142.0, 115.5, 46.6, 8.2
31P-NMR (D2O): -3.65 ppm
MS (ESI, negative mode, m/Z): 200.9, 203.0 (M-H).
Water content: 1.41 % w/w (Karl Fisher). EXAMPLE 5
Inhibition of Pyruvate Kinase
The compounds E-3-chlorophosphoenolpyruvate ditriethyl- ammonium salt (ECPDAT), Z-3- chlorophosphoenolpyruvate tritriethyl- ammonium salt (CPTP), phosphoenol-3-bromo-pyruvic acid mono- cyclohexyl ammonium salt (PBPA), 2-bromooxoethylphosphonic acid mono-cyclohexyl-ammonium salt (BOEPA) and 3-bromopyruvic acid (BrPyA) were tested for their efficiency at inhibiting pyruvate kinase. Pyruvate kinase isolated from rabbit muscle was purchased from Sigma- Aldrich. Pyruvate kinase was assayed indirectly by quantifying ADP production formed in the reaction ATP + pyruvate to ADP + phosphoenolpyruvate. Inhibitors were added to the reaction mixture immediately before the reaction was started by the addition of ATP. E- CPDA, CPTP and PBPA inhibited pyruvate kinase at lower concentrations than BrPyA.
Table 1
Figure imgf000022_0001
EXAMPLE 6
Inhibition of cell proliferation
The compounds of the invention were tested for their inhibition potential of cell proliferation. MCF7 (breast) and SF268 (glioma) cancer cell lines were incubated with different concentrations of the compounds and their viability was assessed using an MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide) assay. The MTT assay is well known in the art (see for example Slater et al., Biochim. Biophys. Acta 77(1963) 383). The cells were incubated with a given inhibitor for 72 hours and assayed. As can be seen in table 2, ECPDA, CPTP, PBPA and BOEPA inhibited cell proliferation in both MCF7 and SF268 cells.
Table 2
I Plate 1 1 ECPDA MCF7
ECPDA uM I NC 0 10 25 50 75 100 200 300 500 uM I
0,085 0,949 0,927 0,899 0,8 0,737 0,66 0,557 0,145 0,1
0,089 0,893 0,901 0,883 0,787 0,7 0,688 0,539 0,146 0,106
0,087 0,868 0,875 0,81 0,729 0,672 0,555 0,142 0,109
0,081 0,894 0,902 0,86 0,774 0,735 0,673 0,925 0,166 0,117
Average 0,0855 0,901 0,91 0,8793 0,7928 0,7253 0,6733 0,644 0,14975 0,108
SEM 0,001708 0,0171 0,0073655 0,0081 0,0078 0,0086 0,0057 0,0938 0,00548 0,003536
A-Blank 0 0,8155 0,8245 0,7938 0,7073 0,6398 0,5878 0,5585 0,06425 0,0225
% 100 101,10362 97,333 86,726 78,449 72,072 68,486 7,8786 2,759044
SEM 2,096 0,9031833 0,9967 0,9595 1,0529 0,7033 11,496 0,67234 0,433542
I I
I Plate 1 2 CPTP/MCF7 I
CPTP uM NC 0 10 25 50 75 100 200 300 500
0,092 0,914 0,905 0,897 0,929 0,88 0,868 0,791 0,732 0,676
0,088 0,86 0,855 0,875 0,877 0,872 0,858 0,794 0,738 0,645
0,067 0,853 0,849 0,853 0,879 0,823 0,844 0,761 0,737 0,634
0,084 0,944 0,92 0,907 0,92 0,872 0,883 0,844 0,762 0,689
Average 0,08275 0,8928 0,88225 0,883 0,9013 0,8618 0,8633 0,7975 0,74225 0,661
SEM 0,005498 0,0219 0,0177735 0,012 0,0136 0,0131 0,0082 0,0172 0,00671 0,012891
A-Blank 0 0,81 0,7995 0,8003 0,8185 0,779 0,7805 0,7148 0,6595 0,57825
% 100 98,703704 98,796 101,05 96,173 96,358 88,241 81,4198 71,38889
SEM 2,6979 2,1942542 1,4849 1,6734 1,6116 1,0148 2,1231 0,82875 1,591428
I Plate 2 3 PBPA/MCF7
PBPA uM I 0 10 25 50 75 100 200 300 500 I
I 0,085 0,88 0,867 0,888 0,875 0,894 0,874 0,822 0,76 0,699
0,089 0,882 0,839 0,857 0,875 0,881 0,857 0,842 0,772 0,669
0,088 0,872 0,838 0,869 0,88 0,878 0,854 0,832 0,767 0,687
0,095 0,922 0,84 0,865 0,873 0,88 0,847 0,859 0,783 0,716
Average 0,08925 0,889 0,846 0,8698 0,8758 0,8833 0,858 0,8388 0,7705 0,69275
SEM 0,002097 0,0112 0,0070119 0,0066 0,0015 0,0036 0,0057 0,0079 0,00484 0,009903
A-Blank 0,0065 0,8063 0,76325 0,787 0,793 0,8005 0,7753 0,756 0,68775 0,61
% 99,537 94,228395 97,16 97,901 98,827 95,71 93,333 84,9074 75,30864
SEM 1,384 0,865666 0,8117 0,1843 0,449 0,7074 0,9739 0,59742 1,22255
I Plate 2 4 BOEPA/MCF7
I NC 0 10 25 50 75 100 200 300 500
BOEPA uM 0,086 0,895 0,847 0,854 0,84 0,847 0,84 0,837 0,583 0,42
0,091 0,905 0,835 0,854 0,823 0,844 0,828 0,829 0,595 0,395
0,066 0,917 0,843 0,827 0,797 0,818 0,797 0,8 0,512 0,353
0,107 0,907 0,882 0,885 0,874 0,895 0,883 0,806 0,5 0,383
Average 0,0875 0,906 0,85175 0,855 0,8335 0,851 0,837 0,818 0,5475 0,38775
SEM 0,008451 0,0045 0,0103873 0,0119 0,0161 0,016 0,0178 0,0089 0,02421 0,013913
A-Blank 0 0,8185 0,76425 0,7675 0,746 0,7635 0,7495 0,7305 0,46 0,30025
% 100 93,372022 93,769 91,142 93,28 91,57 89,249 56,2004 36,68296
SEM 0,5509 1,2690644 1,4482 1,9716 1,9605 2,1758 1,0871 2,95775 1,699777 I Plate 4 1 ECPDA/SF268 I
ECPDA uM NC 0 10 25 50 75 100 200 300 500
0,083 0,775 0,802 0,759 0,644 0,421 0,293 0,195 0,149 0,116
0,088 0,783 0,793 0,752 0,633 0,437 0,323 0,2 0,15 0,124
0,089 0,774 0,787 0,767 0,592 0,454 0,334 0,232 0,156 0,128
Average 0,095 0,803 0,777 0,78 0,644 0,478 0,361 0,216 0,16 0,131
SEM 0,001607 0,1943 2,3015021 6,0602 12,344 18,641 24,921 49,948 74,9621 124,9693
A-Blank 0,01 0,698 0,672 0,675 0,539 0,373 0,256 0,111 0,055 0,026
% 83,194 80,095352 80,453 64,243 44,458 30,513 13,23 6,55542 3,098927
SEM 23,164 274,31491 722,31 1471,3 2221,8 2970,3 5953,2 8934,69 14895,03
I Plate 4 2 CPTP/SF268
CPTP uM L NC 0 10 25 50 75 100 200 300 500
0,086 0,78 0,805 0,775 0,771 0,733 0,739 0,629 0,514 0,348
0,087 0,777 0,73 0,763 0,761 0,715 0,752 0,607 0,484 0,349
0,064 0,772 0,736 0,774 0,764 0,736 0,739 0,599 0,443 0,318
0,108 0,787 0,829 0,801 0,771 0,761 0,796 0,613 0,497 0,351
Average 0,08625 0,779 0,775 0,7783 0,7668 0,7363 0,7565 0,612 0,4845 0,3415
SEM 0,008985 0,0031 0,0247689 0,0081 0,0025 0,0095 0,0135 0,0064 0,01514 0,007858
A-Blank 0 0,6928 0,68875 0,692 0,6805 0,65 0,6703 0,5258 0,39825 0,25525
% 100 99,422591 99,892 98,232 93,829 96,752 75,893 57,4883 36,8459
SEM 0,4527 3,5754503 1,1629 0,3651 1,3661 1,9514 0,9168 2,18484 1,134337
I Plate 5 3 PBPA/SF268
PBPA uM |_ NC 0 10 25 50 75 100 200 300 500
0,083 0,766 0,785 0,805 0,766 0,772 0,742 0,726 0,642 0,602
0,086 0,791 0,804 0,763 0,773 0,789 0,76 0,709 0,649 0,6
0,086 0,787 0,773 0,803 0,787 0,789 0,735 0,709 0,623 0,59
0,094 0,772 0,757 0,801 0,778 0,769 0,753 0,722 0,641 0,617
Average 0,08725 0,779 0,77975 0,793 0,776 0,7798 0,7475 0,7165 0,63875 0,60225
SEM 0,002358 0,006 0,0099111 0,01 0,0044 0,0054 0,0056 0,0044 0,00554 0,005573
A-Blank 0,001 0,6928 0,6935 0,7068 0,6898 0,6935 0,6613 0,6303 0,5525 0,516
% 100 100,10826 102,02 99,567 100,11 95,453 90,978 79,7546 74,48575
SEM 0,8601 1,4306839 1,4483 0,6374 0,776 0,8048 0,6361 0,8002 0,804529
I Plate i 5 4 BOEPA/SF268 I
BOEPA uM[ NC 0 10 25 50 75 100 200 300 500
0,087 0,78 0,764 0,75 0,781 0,719 0,669 0,419 0,18 0,117
0,086 0,78 0,791 0,752 0,78 0,764 0,72 0,429 0,184 0,124
0,068 0,744 0,781 0,773 0,754 0,741 0,7 0,479 0,138 0,103
0,108 0,778 0,781 0,793 0,79 0,763 0,732 0,472 0,181 0,147
Average 0,08725 0,771 0,77925 0,767 0,776 0,747 0,705 0,4498 0,17075 0,12275
SEM 0,00818 0,009 0,005603 0,01 0,008 0,011 0,014 0,0151 0,01095 0,00919
A-Blank 0 0,683 0,692 0,68 0,689 0,66 0,618 0,3625 0,0835 0,0355
% 100 101,2806 99,49 100,8 96,52 90,45 53,055 12,221 5,19576
SEM 1,295 0,82008 1,479 1,134 1,561 2,015 2,2062 1,60259 1,34456 Legend for Table 2:
NC: no cells; A-Blank: Average-Blank; %: [A-blank]-[A-Blank]controi/[A- Blank]controi ; SEM: Standard error of the mean. Concentrations are in μM and the data are O. D. readings at 570nm.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. An inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula I :
Figure imgf000027_0001
wherein,
X represents a halide, a sulfonate, an alkoxide, an amine-oxide or sulfonium salt, or sulfoxide;
Y represents oxygen, sulphur or CH2;
Z represents oxygen, sulphur or NR;
R and R' represent H, alkyl, aryl or heteroaryl esters; and any isomers or salts thereof.
2. An inhibitor of claim 1 , which is 2-bromo-1-oxoethylphosphonic acid.
3. An inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula Il :
Figure imgf000027_0002
wherein,
X and Y represent H, halide, or alkyl group; A is o Il O
O— — S-OR or c—Si— OR' or O— C- R
Figure imgf000027_0003
R, R' and R" represent H, alkyl, aryl or heteroaryl esters; and any isomers or salts thereof.
4. An inhibitor of claim 3, comprises a compound of formula III:
Figure imgf000028_0001
wherein
X, Y, R R, R' and R" are as defined in claim 3; and any isomers or salts thereof.
5. An inhibitor of claim 4, which is phosphoenol-3-bromopyruvic acid.
6. An inhibitor of claim 4 which is selected from Z and E-3- chlorophosphoenolpyruvate.
7. An inhibitor of claim 6 which is E-3-chlorophosphoenolpyruvate.
8. An inhibitor of claim 3, comprises a compound of formula IV:
Figure imgf000028_0002
wherein
X, Y, R R, R1 and R" are as defined in claim 3; and any isomers or salts thereof.
9. The inhibitor of any of claims 1 to 8, wherein the halide is selected from the group consisting of: fluoride, bromide, chloride, and iodide.
10. An inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula V :
Figure imgf000029_0001
wherein
X represents Cl or Br, and any isomers or salts thereof.
11. An inhibitor of pyruvate kinase and of ATP production which comprises a compound of formula VIII :
Figure imgf000029_0002
wherein
X represents Cl or Br, and any isomers or salts thereof.
12. A method of treating cancer in a subject comprising administering to the subject an effective amount of an inhibitor according to any of claims 1 to 11.
13. The method of claim 12, which further comprising administering a second chemotherapeutic agent.
14. The method of claim 13, wherein the second chemotherapeutic agent is selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2-chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin-dunomycin, dexamethosone, doxurubicin, docetaxol, trastuzumab, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interfereon alfa n3, irinotecan, leucovorin calcium, leuprolide, levamisole, lomustine, inegestrol, melphalan, L-sarcosylin, melphalan hydrochloride, MESNA, mechlorethamine, methotrexate, mitomycin, mitoxantrone, mercaptopurine, paclitaxel, plicamycin, prednisone, procarbazine, streptozocin, tamoxifen, 6-thioguanine, thiotepa, vinblastine, vincristine and vinorelbine tartrate.
15. The method of claim 12, wherein the effective amount of the inhibitor is delivered by direct intravenous or intraarterial injection to a tumor, or using a delivery system, or administered orally in the form of a tablet, capsule or liquid.
16. The method of claim 15, wherein the tumor is selected from the group consisting of colorectal, glioma, liver, breast, lung or ovarian tumor.
17. The method of claim 15, wherein the tumor is a liver tumor and the inhibitor is delivered to a hepatic artery.
18. The method of claim 17, wherein the inhibitor is delivered by transcatheteter hepatic artery injection.
19. The methods of any of claims 14 to 16, wherein the inhibitor or second chemotherapeutic agent is delivered using a delivery system.
20. The method of claim 19, wherein the delivery system is selected from the group consisting of micelles, liposomes, transdermal and inhalation.
21. A composition for treating cancer in a subject comprising an effective amount of an inhibitor according to any of claims 1 to 11 in association with a pharmaceutically acceptable carrier.
22. The composition of claim 21 , which further comprises a second chemotherapeutic agent.
23. The composition of claim 22, wherein the second chemotherapeutic agent is selected from the group consisting of: altretamine, asparaginase, BCG, bleomycin sulfate, busulfan, carboplatin, carmusine, chlorambucil, cisplatin, claladribine, 2-chlorodeoxyadenosine, cyclophosphamide, cytarabine, dacarbazine imidazole carboxamide, dactinomycin, daunorubicin-dunomycin, dexamethosone, doxurubicin, docetaxol, trastuzumab, etoposide, floxuridine, fluorouracil, fluoxymesterone, flutamide, fludarabine, goserelin, hydroxyurea, idarubicin HCL, ifosfamide, interferon alfa, interferon alfa 2a, interferon alfa 2b, interfereon alfa n3, irinotecan, leucovorin calcium, leuprolide, levamisole, lomustine, inegestrol, melphalan, L-sarcosylin, melphalan hydrochloride, MESNA, mechlorethamine, methotrexate, mitomycin, mitoxantrone, mercaptopurine, paclitaxel, plicamycin, prednisone, procarbazine, streptozocin, tamoxifen, 6-thioguanine, thiotepa, vinblastine, vincristine and vinorelbine tartrate.
24. A use of an inhibitor as claimed in any one of claim 1-11 for treating cancer in a subject, which comprises administering an effective amount of said inhibitor to said subject.
25. A use of an inhibitor as claimed in any one of claim 1-11 for preparing a medicament to treat cancer in a subject.
26. A use of the composition as claimed in any one of claim 21-23 for treating cancer in a subject, which comprises administering an effective amount of said inhibitor to said subject.
PCT/CA2006/000871 2005-05-27 2006-05-29 Novel inhibitors of pyruvate kinase as therapeutic agents for cancer WO2006125323A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06741580A EP1891082A4 (en) 2005-05-27 2006-05-29 Novel inhibitors of pyruvate kinase as therapeutic agents for cancer
US11/915,664 US8026278B2 (en) 2005-05-27 2006-05-29 Inhibitors of pyruvate kinase as therapeutic agents for cancer
CA2610647A CA2610647C (en) 2005-05-27 2006-05-29 Novel inhibitors of pyruvate kinase as therapeutic agents for cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68497905P 2005-05-27 2005-05-27
US60/684,979 2005-05-27

Publications (1)

Publication Number Publication Date
WO2006125323A1 true WO2006125323A1 (en) 2006-11-30

Family

ID=37451615

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/000871 WO2006125323A1 (en) 2005-05-27 2006-05-29 Novel inhibitors of pyruvate kinase as therapeutic agents for cancer

Country Status (4)

Country Link
US (1) US8026278B2 (en)
EP (1) EP1891082A4 (en)
CA (1) CA2610647C (en)
WO (1) WO2006125323A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011050211A2 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719167A (en) * 1953-04-13 1955-09-27 Ciba Ltd Compounds containing phosphorus and process therefor
US2956919A (en) * 1955-05-23 1960-10-18 Monsanto Chemicals 1-oxo-2-halo phosphonates
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
US20040198750A1 (en) * 2003-04-03 2004-10-07 Jeremy Green Compositions useful as inhibitors of protein kinases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214879B1 (en) * 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719167A (en) * 1953-04-13 1955-09-27 Ciba Ltd Compounds containing phosphorus and process therefor
US2956919A (en) * 1955-05-23 1960-10-18 Monsanto Chemicals 1-oxo-2-halo phosphonates
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
US20040198750A1 (en) * 2003-04-03 2004-10-07 Jeremy Green Compositions useful as inhibitors of protein kinases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRITTELLI D.R.: "A study of the reaction of 2-haloacyl halides with trialkyl phosphites. Synthesis of (2-substituted acyl) phosphonates", J. ORGANIC CHEMISTRY, vol. 50, no. 11, 1985, pages 1845 - 1847, XP003005333 *
CSUK R. ET AL: "Allylphosphonates by heteroanalogous zinc-silver/graphite mediated Dreiding-Schmidt reactions", JOURNAL OF CARBOHYDRATE CHEMISTRY, vol. 18, no. 3, 1999, pages 285 - 295, XP008075142 *
GUREVICH I.E. ET AL: "Dimethyl-3-chloroprop-1-en-2-ylphosphonate. Part 3. Alkylation of anionic O and C nucleophiles and preparation of 1-alkenyl-2-phosphonates", PHOSPHORUS, SULFUR AND SILICON AND RELATED ELEMENTS, vol. 148, 1999, pages 61 - 78, XP008075139 *
KNOCHEL P. ET AL.: "Addition of functionalized allylic bromides to terminal alkynes", TETRAHEDRON LETTERS, vol. 25, no. 14, 1984, pages 1475 - 1478, XP003005334 *
KNOCHEL P. ET AL.: "Synthese de dienes-1,4-fonctionnalises par addition de zinciques allyliques fonctionnalises sur des alcynes vrais et leur cyclisation en heterocycles ou carbocycles", J. ORGANOMETALLIC CHEMISTRY, vol. 309, no. 1-2, 1986, pages 1 - 23, XP003005332 *
KRAWCZYK H.: "A convenient route to monodealkylation of diethyl phosphonates", SYNTHETIC COMMUNICATIONS, vol. 27, no. 18, 1997, pages 3151 - 3161, XP008075143 *
See also references of EP1891082A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011050211A2 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
EP3561077A1 (en) 2009-10-21 2019-10-30 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders

Also Published As

Publication number Publication date
EP1891082A4 (en) 2009-02-18
CA2610647C (en) 2015-02-03
CA2610647A1 (en) 2006-11-30
US20080311183A1 (en) 2008-12-18
EP1891082A1 (en) 2008-02-27
US8026278B2 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
JP6932227B2 (en) Carbidopa and L-dopa prodrugs and how to use them
US5447922A (en) α-phosphonosulfinic squalene synthetase inhibitors
US8378100B2 (en) Phosphonate derivatives as autotaxin inhibitors
JP5244917B2 (en) C2-C5-alkyl-imidazole-bisphosphonates
GB2118042A (en) Pharmaceutical compositions containing biphosphonic acids
PL207589B1 (en) Selective crystallization of 3−pyridyl−1−hydroxyethylidene−1,1−bisphosphonic acid sodium as the hemipentahydrate or monohydrate
CZ121793A3 (en) Novel derivatives of methylbisphosphonic acid, process of their preparation and a pharmaceutical mixture therefrom
WO1989011278A1 (en) Cyclophosphamide analogs useful as anti-tumor agents
US5278153A (en) Aryl and heteroaryl (phosphinylmethyl)phosphonate squalene synthetase inhibitors and method
CZ119893A3 (en) Novel derivatives of methylene-bisphosphonic acid
US8026278B2 (en) Inhibitors of pyruvate kinase as therapeutic agents for cancer
US4908356A (en) Aldophosphamide derivatives useful as antitumor agents
FI91966C (en) Method for the preparation of pharmacologically valuable alkylphosphonoserines
EP2493905B1 (en) Bisphosphonate compounds for treating bone metabolism disorders
JPH0617307B2 (en) Antitumor agent
US5254544A (en) Hydroxyphosphinyl phosphonate squalene synthetase inhibitors and method
MX2011006605A (en) Phenylalkyl-imidazole-bisphosphonate compounds.
WO2008076826A1 (en) Pyrophosphoramide alkylators
CA2159850A1 (en) Phosphonosulfonate squalene synthetase inhibitor salts and method
AU9543798A (en) Novel methylenebisphosphonic acid derivatives
HU199772B (en) Process for production of acid additioned salts of fluorized diamin-hexin and medical compositions containing them
CA2888194A1 (en) Substituted indole derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2610647

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006741580

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006741580

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11915664

Country of ref document: US

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)